Denovo Biopharma is Drug Discovery in China that focus on less adverse effects business. They cover business area such as developer, personalized drug, biomarker, therapeutic area, oncology, metabolic, cardiology, immunology, neurology, archived clinical sample, biotech and pharmaceutical company, new clinical trial, significant efficacy, less adverse effect.
-
Less Adverse Effects
-
A1409-1410, Building 2, No. 452, 6th Baiyang Street
Hangzhou Economic & Tech Development Zone
Hangzhou, Zhejiang 100005
China
Private
developerpersonalized drugbiomarkertherapeutic areaoncologymetaboliccardiologyimmunologyneurologyarchived clinical samplebiotech and pharmaceutical companynew clinical trialsignificant efficacyless adverse effect
* We use standard office opening hours in near Denovo Biopharma's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Denovo Biopharma is Drug Discovery business from China that founded in - ( years old in ), Denovo Biopharma business is focusing on Less Adverse Effects.
Denovo Biopharma headquarter office and corporate office address is located in A1409-1410, Building 2, No. 452, 6th Baiyang Street Hangzhou Economic & Tech Development Zone Hangzhou, Zhejiang 100005 China.
Denovo Biopharma was founded in China.
In , Denovo Biopharma is currently focus on less adverse effects sector.
Above is snippet of Google Trends for "less adverse effects" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Denovo Biopharma, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
